Pharma Industry News
A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.
Why Risk Mitigation Tools Are A Hard Sell In Pharma-And What Might Change That
George Achilleos is the CEO of NetraMark Holdings Inc. Drug development has a strange economic problem. A pharmaceutical company may be willing to spend tens or even hundreds of millions of dollars advancing a drug into a major clinical…
Adarx Pharma Shares Climb 30% After $446.3 Million Upsized IPO
Adarx Pharmaceuticals Inc., a late-stage developer of gene therapies, jumped 30% after raising $446.3 million in an upsized initial public offering. Shares of the San Diego-based firm, which counts OrbiMed Advisors as a backer, opened at $22.10…
Pharma stock soars 150% on injectables deal with Wegovy maker Novo
The Swedish drug-delivery company agreed to license its PharmaShell technology to Novo Nordisk for up to five development programs targeting obesity, type 2 diabetes and other cardiometabolic conditions. Novo Nordisk will use the technology to…
AI risk raises the bar for outsourced pharma marketing deals
Axios Pro Exclusive Content 51 mins ago…
Royalty Pharma (NASDAQ:RPRX) Rating Lowered to Buy at Wall Street Zen
Royalty Pharma (NASDAQ:RPRX - Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a 'strong-buy' rating to a 'buy' rating in a report issued on Saturday, Wall Street Zen reports. How Royalty Pharma Prints Cash…
Kanpur Murder Twist: Rs 40 Lakh Debt, Property Dispute Put Pharma Dealer's Son Under Scanner | Dynamite News
Post Published By: Rishira Jain Updated: 25 September 2026, 3:38 PM IST Kanpur: A shocking twist has emerged in the murder case of Uttar Pradesh pharmaceutical businessman Vineet Manocha, with police claiming that the victim's own son allegedly…
Ascendis Pharma A/S (NASDAQ:ASND) Cut to Hold at Wall Street Zen
Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) was downgraded by equities researchers at Wall Street Zen from a 'buy' rating to a 'hold' rating in a report issued on Saturday, Wall Street Zen reports. Get Ascendis Pharma A/S alerts: Can…
Ascendis Pharma A/S (NASDAQ:ASND) Stock Rated 'Buy' by Wall Street Brokerages
Shares of Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) have received a consensus recommendation of 'Buy' from the twenty-one research firms that are covering the company, MarketBeat reports. One research analyst has rated the stock with a…
BridgeBio Pharma Eyes Four Global Launches by 2027 as Attruby Nears Blockbuster Status
The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions BridgeBio Pharma NASDAQ: BBIO expects 2027 to be a transformative year as it expands from one commercial product to four globally launched therapies, President and CFO…
State Street Corp Makes New $10.50 Million Investment in Avalyn Pharma Inc. $AVLN
State Street Corp acquired a new stake in Avalyn Pharma Inc. (NASDAQ:AVLN - Free Report) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 318,995 shares of the company's stock, valued at…
How Chinese biotech is graduating from licensing deals to broader partnerships
Chinese biotech deal making is moving beyond the licensing of individual drug candidates, as the country transforms from a follower to a global innovation leader, according to analysts. The latest transaction underscores that shift. Beijing-based…
Pfizer: Buy Before The Street Catches Up To Its Own Numbers (NYSE:PFE)
Pfizer is rated buy, not for deep value, but due to a disconnect between management's bullish long-term growth guidance and a flat consensus earnings curve. Consensus models a permanent post-2026 revenue/EPS decline, but PFE's $13B product base is…
Orion Corporation: Acquisition of own shares during week 39, 2026
Orion Corporation: Acquisition of own shares during week 39, 2026 The share buybacks form part of the share buyback programme that Orion Corporation announced on 27 August 2026. The buyback programme runs from 1 September 2026 until no later than…
Viking Therapeutics Soared After Its Latest GLP-1 Data. Is It Too Late to Buy?
Today, a very valuable market -- one heading toward $100 billion by the end of the decade -- is dominated by two pharma giants, Eli Lilly and Novo Nordisk. And this is the weight loss drug market. Lilly and Novo each sell GLP-1 drugs, products that…
The Nascent Crescent Biopharma Thesis: One Year Later And Things Are Steady (NASDAQ:CBIO)
Crescent Biopharma remains a Buy, balancing early clinical progress with robust liquidity and sector opportunity. CBIO's lead asset, CR-001, is in phase 1/2 trials with proof-of-concept data expected in Q1 2027; additional pipeline assets advance…
Receive a Daily briefing on Pharma Industry News
Get Started